According to NICE guidelines, women experiencing vasomotor symptoms during menopause can be prescribed fluoxetine, a selective serotonin uptake inhibitor (SSRI). While clonidine is also approved for treating these symptoms, its effectiveness is not well-established and it can cause side effects such as dry mouth, sedation, depression, and fluid retention. Gabapentin is being studied for its potential to reduce hot flushes, but more research is needed.

Managing Menopause: Lifestyle Modifications, Hormone Replacement Therapy, and Non-Hormone Replacement Therapy

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 consecutive months. Menopausal symptoms are common and can last for up to 7 years, with varying degrees of severity and duration. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage menopausal symptoms such as hot flushes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended. For women who cannot or do not want to take HRT, non-hormonal treatments such as fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturizers for vaginal dryness, and cognitive behavior therapy or antidepressants for psychological symptoms can be prescribed.

HRT is a treatment option for women with moderate to severe menopausal symptoms. However, it is contraindicated in women with current or past breast cancer, any estrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia. HRT brings certain risks, including venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer. Women should be advised of these risks and the fact that symptoms typically last for 2-5 years.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence of symptoms in the short term. However, in the long term, there is no difference in symptom control. Women who experience ineffective treatment, ongoing side effects, or unexplained bleeding should be referred to secondary care. Overall, managing menopause requires a personalized approach that takes into account a woman’s medical history, preferences, and individual symptoms.

Contraception is still necessary after menopause. Women who are over 50 years old should use contraception for at least 12 months after their last period, while those under 50 years old should use it for at least 24 months after their last period.

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. On average, women in the UK experience menopause at the age of 51. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

Screening for Down’s syndrome, which involves the nuchal scan, is conducted during antenatal care at 11-13+6 weeks. The combined test, which also includes the nuchal scan, is performed during this time frame. However, if the patient prefers to undergo the screening at a later stage of pregnancy, they can opt for the triple or quadruple test between 15 and 20 weeks.

NICE guidelines recommend 10 antenatal visits for first pregnancies and 7 for subsequent pregnancies if uncomplicated. The purpose of each visit is outlined, including booking visits, scans, screening for Down’s syndrome, routine care for blood pressure and urine, and discussions about labour and birth plans. Rhesus negative women are offered anti-D prophylaxis at 28 and 34 weeks. The guidelines also recommend discussing options for prolonged pregnancy at 41 weeks.

If the woman does not approve of hormonal treatments, alternatives such as tranexamic acid or NSAIDs can be utilized according to NICE CG44.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progestogen hormone etonogestrel to prevent ovulation and thicken cervical mucus. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

The primary cause of breast abscess in lactational women is Staphylococcus aureus, while Candida species is not a frequent culprit. On the other hand, Group B streptococcus and Klebsiella pneumoniae are responsible for breast abscess in non-lactating women.

Breast Abscess: Causes and Management

Breast abscess is a condition that commonly affects lactating women, with Staphylococcus aureus being the most common cause. The condition is characterized by the presence of a tender, fluctuant mass in the breast. To manage the condition, healthcare providers may opt for either incision and drainage or needle aspiration, typically using ultrasound. Antibiotics are also prescribed to help manage the infection.

Breast abscess is a condition that can cause discomfort and pain in lactating women. It is caused by Staphylococcus aureus, a common bacterium that can infect the breast tissue. The condition is characterized by the presence of a tender, fluctuant mass in the breast. To manage the condition, healthcare providers may opt for either incision and drainage or needle aspiration, typically using ultrasound. Antibiotics are also prescribed to help manage the infection. Proper management of breast abscess is crucial to prevent complications and ensure a speedy recovery.

If a woman experiences secondary amenorrhoea and has low levels of gonadotrophins, it suggests that the cause is related to the hypothalamus. High levels of gonadotrophins would indicate premature ovarian failure, while high levels of LH and androgens would suggest polycystic ovarian syndrome. Normal levels of prolactin and thyroxine have been observed in this woman.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

Endometriosis is characterized by pelvic pain, dysmenorrhoea, dyspareunia, and subfertility. The main indicators of this condition are cyclic abdominal pain and deep dyspareunia, which may be accompanied by fertility issues. Unlike endometriosis, pelvic inflammatory disease does not typically cause pain during menstruation. A bicornuate uterus, which is a congenital anomaly resulting in a heart-shaped uterus, is associated with a higher risk of recurrent miscarriages. Cervical carcinomas are usually accompanied by abnormal bleeding, such as post-coital and inter-menstrual bleeding, but they are unlikely to have been present for as long as three years.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Hyperreflexia and clonus are commonly observed in patients with severe pre-eclampsia, while a decrease in platelet count may indicate the onset of HELLP syndrome.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

Hormone replacement therapy (HRT) is a treatment that involves administering synthetic oestrogen and progestogen to women experiencing menopausal symptoms. HRT can be given as local (creams, pessaries, rings) or systemic therapy (oral drugs, transdermal patches and gels, implants) and may contain oestrogen alone, combined oestrogen and progestogen, selective oestrogen receptor modulator, or gonadomimetics. The average age for menopause is around 50-51 years, and symptoms include hot flushes, insomnia, weight gain, mood changes, and irregular menses. HRT should be initiated at the lowest possible dosage and titrated based on clinical response. However, HRT is not recommended for women who have undergone hysterectomy due to the risk of endometrial hyperplasia, a precursor to endometrial cancer. HRT may also increase the risk of breast cancer and heart attacks, and non-hormonal options should be considered for menopausal effects in women who have previously had breast cancer. There is no evidence to suggest that HRT is associated with an increased or decreased risk of developing cervical cancer, and observational studies of systemic HRT after breast cancer are generally reassuring. Oestrogen is believed to be a growth factor that enhances cholinergic neurotransmission and prevents oxidative cell damage, neuronal atrophy, and glucocorticoid-induced neuronal damage, which may help prevent dementia.

If the COC is not started on the first day of the next period, it is important to follow the standard guidelines and use condoms for 7 days.

Special Situations for Combined Oral Contraceptive Pill

Concurrent antibiotic use has been a concern for many years in the UK, as doctors have advised that it may interfere with the effectiveness of the combined oral contraceptive pill. However, this approach is not taken in the US or most of mainland Europe. In 2011, the Faculty of Sexual & Reproductive Healthcare updated their guidelines to abandon the extra precautions previously advised during antibiotic treatment and for 7 days afterwards. The latest edition of the British National Formulary (BNF) has also been updated to reflect this guidance, although precautions should still be taken with enzyme-inducing antibiotics such as rifampicin.

When it comes to switching combined oral contraceptive pills, the BNF and Faculty of Sexual & Reproductive Healthcare (FSRH) appear to give contradictory advice. The FSRH’s Combined Oral Contraception guidelines state that the pill-free interval does not need to be omitted, while the BNF advises missing the pill-free interval if the progesterone changes. Given this uncertainty, it is best to follow the BNF’s advice.

If a pregnant woman is exposed to chickenpox before 20 weeks and has a negative IgG test, it indicates that she is not immune to the virus or has not been previously exposed to it. In such cases, it is recommended to administer varicella-zoster immunoglobulin (VZIG) as soon as possible, which can be effective up to 10 days after exposure. It is not necessary to inform public health as chickenpox is not a notifiable disease.

If a pregnant woman develops a chickenpox rash, VZIG has no therapeutic benefit and should not be used. However, antiviral agents like aciclovir can be given within 24 hours of the rash onset. It is important to note that antiviral agents are recommended for post-exposure prophylaxis for immunosuppressed individuals.

Women who are not immune to varicella-zoster can receive the vaccine before pregnancy or after delivery, but it should not be administered during pregnancy. Therefore, option D cannot be correct in any situation.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

For patients experiencing recurrent vaginal candidiasis, it is recommended to consider an induction-maintenance regime of oral fluconazole. Over the counter antifungal treatments, such as clotrimazole cream, are typically effective for one-off episodes of thrush. However, in cases of recurrent symptoms, a more comprehensive treatment plan may be necessary. It is important to ensure that the patient is not taking SSRI medications or has hypersensitivity to ‘azole’ antifungal medications before prescribing fluconazole. It should be noted that IM ceftriaxone and oral ciprofloxacin are used to manage Neisseria gonorrhoea, not thrush, and oral metronidazole is used to manage bacterial vaginosis, not thrush.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

The most significant risk factor for cervical cancer is infection with the human papillomavirus (HPV), particularly types 16, 18, and 33. Among the approximately 15 types of HPV that are considered high-risk for cervical cancer, HPV 16 and 18 are responsible for about 70% of cases. HPV 6 and 11, on the other hand, are associated with the formation of genital warts.

Understanding Cervical Cancer: Risk Factors and Mechanism of HPV

Cervical cancer is a type of cancer that affects the cervix, which is the lower part of the uterus. It is most commonly diagnosed in women under the age of 45, with the highest incidence rates occurring in those aged 25-29. The cancer can be divided into two types: squamous cell cancer and adenocarcinoma. Symptoms may include abnormal vaginal bleeding, postcoital bleeding, intermenstrual bleeding, or postmenopausal bleeding, as well as vaginal discharge.

The most important factor in the development of cervical cancer is the human papillomavirus (HPV), particularly serotypes 16, 18, and 33. Other risk factors include smoking, human immunodeficiency virus, early first intercourse, many sexual partners, high parity, and lower socioeconomic status. While the association between combined oral contraceptive pill use and cervical cancer is sometimes debated, a large study published in the Lancet confirmed the link.

The mechanism by which HPV causes cervical cancer involves the production of oncogenes E6 and E7 by HPV 16 and 18, respectively. E6 inhibits the p53 tumour suppressor gene, while E7 inhibits the RB suppressor gene. Understanding the risk factors and mechanism of HPV in the development of cervical cancer is crucial for prevention and early detection. Regular cervical cancer screening is recommended for all women.

Breast cancer screening is offered to women aged 50-70 years through the NHS Breast Screening Programme. Mammograms are provided every three years, and women over 70 years are encouraged to make their own appointments. While the effectiveness of breast screening is debated, it is estimated that the programme saves around 1,400 lives annually.

For those with familial breast cancer, NICE guidelines recommend referral if there is a family history of breast cancer with any of the following: diagnosis before age 40, bilateral breast cancer, male breast cancer, ovarian cancer, Jewish ancestry, sarcoma in a relative under 45 years, glioma or childhood adrenal cortical carcinomas, complicated patterns of multiple cancers at a young age, or paternal history of breast cancer with two or more relatives on the father’s side. Women at increased risk due to family history may be offered screening at a younger age. Referral to a breast clinic is recommended for those with a first-degree relative diagnosed with breast cancer before age 40, a first-degree male relative with breast cancer, a first-degree relative with bilateral breast cancer before age 50, two first-degree relatives or one first-degree and one second-degree relative with breast cancer, or a first- or second-degree relative with breast and ovarian cancer.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucus thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

Breast masses are a common concern among women, and it is important to understand the possible causes to determine the appropriate course of action. Here are some of the most common causes of breast masses and their characteristics:

Fibroadenoma: This is the most common cause of breast mass in women under 35 years old. It appears as a singular, firm, rubbery, smooth, mobile, painless mass ranging in size from 1 cm to 5 cm. Ultrasonography reveals a well-defined, hypoechoic, homogeneous mass 1–20 cm in diameter.

Fat Necrosis: This is a benign inflammatory process that occurs when there is saponification of local fat. It can result from direct trauma or nodular panniculitis. The breast mass is usually firm, round, and painless, and there may be a single mass or multiple masses. It may be tender or painful in some people.

Breast Abscess: This usually presents with localised breast oedema, erythema, warmth, and pain. There may be associated symptoms of fever, nausea, vomiting, spontaneous drainage from the mass or nipple, and a history of previous breast infection.

Breast Cancer: Early breast cancer may be asymptomatic, and pain and discomfort are typically not present. It is often first detected as an abnormality on a mammogram before it is felt by the patient or healthcare professional. If a lump is discovered, there may be a change in breast size or shape, skin dimpling or skin changes, recent nipple inversion or skin change, or nipple abnormalities.

Lipoma: Lipomas are common benign tumors composed of mature adipocytes that typically present clinically as well-circumscribed, soft, mobile, nontender masses. The classic mammographic appearance of lipoma is a circumscribed fat-containing mass.

It is important to note that the physical examination findings may not always be enough to determine the cause of the breast mass, and further testing may be necessary. Consultation with a healthcare professional is recommended for proper diagnosis and treatment.

Pros and Cons of the Progestogen Only Pill

The progestogen only pill, also known as the mini-pill, is a highly effective form of contraception with a failure rate of only 1 per 100 woman years. One of its advantages is that it does not interfere with sex and its contraceptive effects are reversible upon stopping. It can also be used while breastfeeding and in situations where the combined oral contraceptive pill is contraindicated, such as in smokers over 35 years of age and women with a history of venous thromboembolic disease.

However, the progestogen only pill also has its disadvantages. One of the most common adverse effects is irregular periods, with some users not having periods while others may experience irregular or light periods. It also does not protect against sexually transmitted infections and has an increased incidence of functional ovarian cysts. Common side-effects include breast tenderness, weight gain, acne, and headaches, although these symptoms generally subside after the first few months. Despite its drawbacks, the progestogen only pill remains a popular choice for women seeking a reliable and convenient form of contraception.

The recommended initial treatments for endometriosis are NSAIDs and/or paracetamol. Ibuprofen is the most suitable option for managing pain, and it should be tried first. If the pain is not relieved with one medication, a combination of paracetamol and NSAIDs can be used. If these options are not effective, hormonal treatment can be considered. Codeine is not the first-line treatment and should only be used after other options have been tried. The combined oral contraceptive pill and Mirena coil are also not the initial interventions and should only be considered if analgesia and hormonal treatments are unsuccessful.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Breast Mass Differential Diagnosis

Breast abscesses typically present with localised breast inflammation, pain, and fever. Treatment involves antibiotics and/or incision and drainage. Early breast cancer may be asymptomatic, but may present with changes in breast size or shape, skin dimpling, nipple abnormalities, and axillary lump. Fat necrosis is a benign inflammatory process that can result from trauma or surgery, and presents as a firm, painless mass. Fibroadenoma is the most common cause of breast mass in women aged <35 years, presenting as a singular, firm, rubbery, smooth, mobile, painless mass. Diffuse cystic mastopathy is characterised by cysts of varying sizes due to hormonal changes, but typically presents with multiple lumps and is not associated with inflammation. Clinical examination and biopsy may be needed to differentiate between these conditions.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

Gonorrhoea is best treated with intramuscular ceftriaxone.

Understanding Gonorrhoea: Causes, Symptoms, Microbiology, and Management

Gonorrhoea is a sexually transmitted infection caused by the Gram-negative diplococcus Neisseria gonorrhoeae. It can occur on any mucous membrane surface, including the genitourinary tract, rectum, and pharynx. The incubation period of gonorrhoea is typically 2-5 days. Symptoms in males include urethral discharge and dysuria, while females may experience cervicitis leading to vaginal discharge. Rectal and pharyngeal infections are usually asymptomatic.

Immunisation against gonorrhoea is not possible, and reinfection is common due to antigen variation of type IV pili and Opa proteins. Local complications may develop, including urethral strictures, epididymitis, and salpingitis, which can lead to infertility. Disseminated infection may also occur, with gonococcal infection being the most common cause of septic arthritis in young adults.

Management of gonorrhoea involves the use of antibiotics. Ciprofloxacin used to be the treatment of choice, but there is now increased resistance to it. Cephalosporins are now more widely used, with a single dose of IM ceftriaxone 1g being the new first-line treatment. If ceftriaxone is refused, oral cefixime 400mg + oral azithromycin 2g should be used. Disseminated gonococcal infection (DGI) and gonococcal arthritis may also occur, with symptoms including tenosynovitis, migratory polyarthritis, and dermatitis. Later complications include septic arthritis, endocarditis, and perihepatitis.

Breastfeeding is classified as UKMEC category 4 if done for less than 6 weeks after giving birth, but it is categorized as UKMEC category 2 if done after this period.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

The human papillomavirus (HPV) is a common sexually transmitted infection that can lead to cervical cancer. There are over 100 types of HPV, with types 16 and 18 being high-risk types that are responsible for the majority of cervical cancers. Types 6 and 11 are low-risk types that typically cause benign genital warts. Although not part of the screening process, the Gardasil vaccine can protect against both HPV types 6 and 11.

Contrary to popular belief, not all samples undergo both HPV testing and cytology. Only samples that test positive for high-risk HPV undergo cytology testing. Samples that test negative for high-risk HPV do not require further testing.

In the past, samples were first examined under a microscope (cytology) before HPV testing. However, research has shown that testing for high-risk HPV first is more effective. If a woman tests positive for HPV, she will receive a single letter informing her of her HPV status and whether any abnormal cells were detected.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

When a couple is trying to conceive, it is normal for it to take up to one year for them to be successful. Therefore, medical examinations are typically conducted after one year of consistent attempts to conceive. However, it may be wise to address any physical barriers that could be hindering the couple’s ability to conceive, which is why their sexual history is taken into consideration.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

The recommended first-line treatment for menorrhagia is the intra-uterine system (IUS), which has a high success rate in stopping bleeding and only requires one insertion procedure. Additionally, it provides reliable contraception. Conversely, the copper coil may exacerbate menorrhagia symptoms. While medication such as the progesterone-only pill or combined oral contraceptive pill can be used, they are not the first choice. It would be an extreme measure to refer a woman of child-bearing age for a hysterectomy, especially when there are less invasive and reversible options available to treat menorrhagia, even if the patient expresses no desire for children.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

Nowadays, numerous facilities combine the early ultrasound scan and nuchal scan into a single procedure.

NICE guidelines recommend 10 antenatal visits for first pregnancies and 7 for subsequent pregnancies if uncomplicated. The purpose of each visit is outlined, including booking visits, scans, screening for Down’s syndrome, routine care for blood pressure and urine, and discussions about labour and birth plans. Rhesus negative women are offered anti-D prophylaxis at 28 and 34 weeks. The guidelines also recommend discussing options for prolonged pregnancy at 41 weeks.

Breast cancer risk is increased by HRT, early menarche, late menopause, and COCP, while it is reduced by multiple pregnancy and breastfeeding.

Breast Cancer Risk Factors: Understanding the Predisposing Factors

Breast cancer is a complex disease that can be influenced by various factors. Some of these factors are considered predisposing factors, which means they increase the likelihood of developing breast cancer. One of the most well-known predisposing factors is the presence of BRCA1 and BRCA2 genes, which can increase a person’s lifetime risk of breast and ovarian cancer by 40%. Other predisposing factors include having a first-degree relative with premenopausal breast cancer, nulliparity, having a first pregnancy after the age of 30, early menarche, late menopause, combined hormone replacement therapy, combined oral contraceptive use, past breast cancer, not breastfeeding, ionizing radiation, p53 gene mutations, obesity, and previous surgery for benign disease.

To reduce the risk of developing breast cancer, it is important to understand these predisposing factors and take steps to minimize their impact. For example, women with a family history of breast cancer may choose to undergo genetic testing to determine if they carry the BRCA1 or BRCA2 genes. Women who have not yet had children may consider having their first child before the age of 30, while those who have already had children may choose to breastfeed. Additionally, women who are considering hormone replacement therapy or oral contraceptives should discuss the potential risks and benefits with their healthcare provider. By understanding these predisposing factors and taking proactive steps to reduce their impact, women can help protect themselves against breast cancer.

Breast cancer is the second most common cancer in women and the leading cause of cancer death among women worldwide. Tamoxifen is a drug that can be used to treat breast cancer that requires estrogen to grow. It works by either blocking estrogen receptors or blocking the production of estrogen. For women with estrogen receptor-positive breast cancer, continuing tamoxifen for 10 years instead of stopping at 5 years can further reduce the risk of recurrence and mortality. However, tamoxifen does not affect the risk of breast cancer recurrence. The risk of endometrial cancer is slightly increased with tamoxifen treatment. Screening modalities include breast self-examination, clinical breast examination, mammography, ultrasonography, and magnetic resonance imaging. Early detection is crucial in preventing breast cancer, and screening intervals may need to be shortened to prevent more deaths. Physical examination and biopsy are also important diagnostic approaches. Treatment for breast cancer typically involves surgery, radiation therapy, and adjuvant hormone or chemotherapy when necessary.

The Benefits and Risks of Oral Contraceptives in Relation to Cancer

Oral contraceptives have been a topic of controversy when it comes to their association with cancer in women. However, various studies have shown that they can have both positive and negative effects on different types of cancer.

Breast Cancer:
The Collaborative Group on Hormonal Factors in Breast Cancer conducted a comprehensive analysis and found that current oral contraceptive users and those who had used them within the past 1-4 years had a slightly increased risk of breast cancer. However, the risk is small and resulting tumors spread less aggressively than usual.

Dysmenorrhoea:
For women with primary dysmenorrhoea who do not wish to conceive, a 3-6 month trial of hormonal contraception is reasonable. Monophasic combined oral contraceptives containing 30-35 μg of ethinylestradiol and norethisterone, norgestimate or levonorgestrel are usually the first choice.

Ovarian Cancer:
Oral contraceptives have been noted to prevent epithelial ovarian carcinoma, with studies showing an approximately 40% reduced risk of malignant and borderline ovarian epithelial cancer. This protection lasts for at least 15 years after discontinuation of use and increases with duration of use.

Endometrial Cancer:
Use of oral contraceptives is associated with a 50% reduction of risk of endometrial adenocarcinoma. Protection appears to persist for at least 15 years following discontinuation of use.

Colorectal Cancer:
Women who take combined oral contraceptives are 19% less likely to develop colorectal cancer.

In conclusion, while there are some risks associated with oral contraceptives, they also have benefits in reducing the risk of certain types of cancer. It is important for women to discuss their individual risks and benefits with their healthcare provider when considering the use of oral contraceptives.

Induction of Labour: Reasons, Methods, and Complications

Induction of labour is a medical process that involves starting labour artificially. It is necessary in about 20% of pregnancies due to various reasons such as prolonged pregnancy, prelabour premature rupture of the membranes, diabetes, pre-eclampsia, and rhesus incompatibility. The Bishop score is used to assess whether induction of labour is required, which takes into account cervical position, consistency, effacement, dilation, and fetal station. A score of less than 5 indicates that labour is unlikely to start without induction, while a score of 8 or more indicates that the cervix is ripe and there is a high chance of spontaneous labour or response to interventions made to induce labour.

There are several methods of induction of labour, including membrane sweep, vaginal prostaglandin E2, maternal oxytocin infusion, amniotomy, and cervical ripening balloon. Membrane sweeping involves separating the chorionic membrane from the decidua by rotating the examining finger against the wall of the uterus. Vaginal prostaglandin E2 is the preferred method of induction of labour, unless there are specific clinical reasons for not using it. Uterine hyperstimulation is the main complication of induction of labour, which refers to prolonged and frequent uterine contractions that can cause fetal hypoxemia and acidemia. In rare cases, uterine rupture may occur, which requires removing the vaginal prostaglandins and stopping the oxytocin infusion if one has been started, and tocolysis with terbutaline.

Penile cancer can manifest as an ulcer. The most prevalent form of penile cancer is squamous cell carcinoma, not adenocarcinoma. While stress ulcers cause abdominal pain and bleeding, they are not responsible for this presentation. Herpes outbreaks can be triggered by significant stress, but they typically cause painful lesions that heal within a week. Syphilis, caused by Treponema pallidum, can result in a painless ulcer called a chancre, but it does not cause weight loss, and the lesion usually resolves within six to eight weeks, even without treatment.

Understanding Penile Cancer: Causes, Symptoms, and Treatment

Penile cancer is a rare type of cancer that is typically characterized by squamous cell carcinoma. It is a condition that affects the penis and can cause a variety of symptoms, including penile lump and ulceration. There are several risk factors associated with penile cancer, including human immunodeficiency virus infection, human papillomavirus virus infection, genital warts, poor hygiene, phimosis, paraphimosis, balanitis, and age over 50.

When it comes to treating penile cancer, there are several options available, including radiotherapy, chemotherapy, and surgery. The prognosis for penile cancer can vary depending on the stage of the cancer and the treatment options chosen. However, the overall survival rate for penile cancer is approximately 50% at 5 years.

Antenatal care guidelines were issued by NICE in March 2008, which included specific points for the care of healthy pregnant women. Nausea and vomiting can be treated with natural remedies such as ginger and acupuncture on the ‘p6’ point, as recommended by NICE. Antihistamines, with promethazine as the first-line option according to the BNF, can also be used. Adequate vitamin D intake is crucial for the health of both the mother and baby, and women should be informed about this at their booking appointment. The Chief Medical Officer advises all pregnant and breastfeeding women to take a daily supplement containing 10 micrograms of vitamin D, with particular care taken for those at risk. In 2016, new guidelines were proposed by the Chief Medical Officer regarding alcohol consumption during pregnancy. The government now advises pregnant women not to drink any alcohol to minimize the risk of harm to the baby.

The use of COCP is absolutely contraindicated for individuals who are over 35 years old and smoke more than 15 cigarettes per day. Migraine without aura is not a contraindication, but migraine with aura is a UKMEC 3 contraindication. A BMI of over 35 kg/m2 and a family history of thromboembolism at age less than 45 years are also UKMEC 3 contraindications, but in this case, the patient’s BMI is 25 kg/m2 and her mother had pulmonary embolism at the age of 60 years, so these are not contraindications. Breastfeeding less than 6 weeks post-partum is a UKMEC 4 contraindication, but since the patient is 10 weeks post-partum, it is a UKMEC 2.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

The most common adverse effect associated with the progesterone-only pill, also known as the ‘mini pill’, is irregular vaginal bleeding. Patients should be advised to take the pill at the same time every day without a pill-free break. While oily skin may occur due to increased sebum production, this is not as common as irregular vaginal bleeding. Patients with a history of acne vulgaris who take the progesterone-only pill may experience increased sebum production. The combined oral contraceptive pill (COCP) is commonly used to manage acne vulgaris and hirsutism in polycystic ovarian syndrome. Headaches may occur during the first few months of using hormonal contraception, but this is less likely to occur with the POP as the most common time to experience headaches is during the ‘pill-free interval’. Patients with a history of migraine with aura should be advised of the risks associated with the COCP and migraine with aura and informed that the POP is likely to be a safer alternative. While mood changes have been studied with birth control, there is no definite outcome of recent studies, and epidemiological data gathered by NICE does not support this as the most common adverse effect.

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. When starting the POP, immediate protection is provided if it is commenced up to and including day 5 of the cycle. If it is started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a combined oral contraceptive (COC), immediate protection is provided if the POP is continued directly from the end of a pill packet.

It is important to take the POP at the same time every day, without a pill-free break, unlike the COC. If a pill is missed by less than 3 hours, it should be taken as normal. If it is missed by more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours. Diarrhoea and vomiting do not affect the POP, but assuming pills have been missed and following the above guidelines is recommended. Antibiotics have no effect on the POP, unless they alter the P450 enzyme system, such as rifampicin. Liver enzyme inducers may reduce the effectiveness of the POP.

In addition to these specific guidelines, women should also have a discussion on sexually transmitted infections (STIs) when considering the POP. It is important for women to receive comprehensive counselling on the POP to ensure they are aware of its potential effects and how to use it effectively.

When administering ulipristal acetate to individuals with severe asthma who are using oral steroids to control their condition, caution should be exercised due to the anti-glucocorticoid effect of the medication. The possibility of latex allergy should be considered when recommending barrier contraceptive methods or conducting a physical examination while wearing latex gloves. The failure to use regular contraception is a valid reason to offer emergency contraception following unprotected sexual intercourse. The use of ulipristal as emergency contraception may require caution in individuals with psoriasis, as this condition can be managed with oral steroids. However, it is important to note that oral steroids are only recommended for the individual’s asthma.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

The primary way in which Nexplanon works is by preventing ovulation.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progestogen hormone etonogestrel to prevent ovulation and thicken cervical mucus. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

The symptoms of HELLP syndrome, a severe form of pre-eclampsia, include haemolysis (H), elevated liver enzymes (EL), and low platelets (LP). A patient with this condition may experience malaise, nausea, vomiting, and headache, as well as hypertension with proteinuria and epigastric and/or upper abdominal pain. The patient in this case meets the requirements for a diagnosis of HELLP syndrome.

Liver Complications During Pregnancy

During pregnancy, there are several liver complications that may arise. One of the most common is intrahepatic cholestasis of pregnancy, which occurs in about 1% of pregnancies and is typically seen in the third trimester. Symptoms include intense itching, especially in the palms and soles, as well as elevated bilirubin levels. Treatment involves the use of ursodeoxycholic acid for relief and weekly liver function tests. Women with this condition are usually induced at 37 weeks to prevent stillbirth, although maternal morbidity is not typically increased.

Another rare complication is acute fatty liver of pregnancy, which may occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea and vomiting, headache, jaundice, and hypoglycemia. Severe cases may result in pre-eclampsia. ALT levels are typically elevated, and support care is the primary management until delivery can be performed once the patient is stabilized.

Finally, conditions such as Gilbert’s and Dubin-Johnson syndrome may be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for haemolysis, elevated liver enzymes, and low platelets, is a serious complication that can occur in the third trimester and requires immediate medical attention. Overall, it is important for pregnant women to be aware of these potential liver complications and to seek medical attention if any symptoms arise.

For the treatment of genital warts, topical podophyllum is recommended for multiple, non-keratinised warts, while cryotherapy is recommended for solitary, keratinised warts. Cryotherapy can also be used as an initial treatment for genital warts.

Understanding Genital Warts

Genital warts, also known as condylomata accuminata, are a common reason for visits to genitourinary clinics. These warts are caused by various types of the human papillomavirus (HPV), with types 6 and 11 being the most common culprits. It is important to note that HPV, particularly types 16, 18, and 33, can increase the risk of cervical cancer.

The warts themselves are small, fleshy protrusions that are typically 2-5mm in size and may be slightly pigmented. They can cause discomfort, itching, and even bleeding. Treatment options for genital warts include topical podophyllum or cryotherapy, depending on the location and type of lesion. Topical agents are generally used for multiple, non-keratinised warts, while solitary, keratinised warts respond better to cryotherapy. Imiquimod, a topical cream, is often used as a second-line treatment. It is important to note that genital warts can be resistant to treatment, and recurrence is common. However, most anogenital HPV infections clear up on their own within 1-2 years without intervention.

Women who have recently given birth, whether they are breastfeeding or not, can begin taking the progesterone-only pill at any time postpartum.

It is safe to use progesterone-only pills while breastfeeding, and there is no need to wait for a specific amount of time before starting them. If the pills are started after 21 days, it is recommended to use additional protection for the first 2 days. However, if the woman starts taking the pills immediately, there is no need for extra protection.

Delaying the start of progesterone-only pills can increase the risk of unwanted pregnancy. Therefore, it is important to begin taking them as soon as possible, regardless of whether the woman is breastfeeding or not.

In summary, there is no contraindication to starting progesterone-only pills during the first 21 days postpartum, and breastfeeding does not affect the decision to start them. Women can continue breastfeeding while taking these pills.

After giving birth, women need to use contraception after 21 days. The progestogen-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progestogen enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

If a woman with large fibroids is experiencing fertility issues, the most effective treatment option that also preserves her ability to conceive in the future is myomectomy. However, depending on the specifics of the procedure, the woman may need to consider delivery options, such as a caesarean section, due to the risk of uterine rupture.

While GnRH agonists can shrink fibroids and make them easier to remove surgically, they also temporarily turn off the ovaries, inhibiting ovulation and making pregnancy impossible during treatment. Additionally, fibroids tend to regrow after treatment is stopped. However, when combined with myomectomy, GnRH agonists can be a suitable treatment option.

Endometrial ablation, on the other hand, destroys the endometrial lining, making it impossible for an embryo to implant. Uterine artery embolisation is also not recommended for women trying to conceive, as it significantly reduces blood supply to the uterus, making it impossible for a fetus to implant and grow.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

First-line treatment for dysmenorrhoea involves NSAIDs, which work by inhibiting the synthesis of prostaglandins, a major contributor to menstrual pain.

Dysmenorrhoea is a condition where women experience excessive pain during their menstrual period. There are two types of dysmenorrhoea: primary and secondary. Primary dysmenorrhoea affects up to 50% of menstruating women and is not caused by any underlying pelvic pathology. It usually appears within 1-2 years of the menarche and is thought to be partially caused by excessive endometrial prostaglandin production. Symptoms include suprapubic cramping pains that may radiate to the back or down the thigh, and pain typically starts just before or within a few hours of the period starting. NSAIDs such as mefenamic acid and ibuprofen are effective in up to 80% of women, and combined oral contraceptive pills are used second line for management.

Secondary dysmenorrhoea, on the other hand, typically develops many years after the menarche and is caused by an underlying pathology. The pain usually starts 3-4 days before the onset of the period. Causes of secondary dysmenorrhoea include endometriosis, adenomyosis, pelvic inflammatory disease, intrauterine devices, and fibroids. Clinical Knowledge Summaries recommend referring all patients with secondary dysmenorrhoea to gynaecology for investigation. It is important to note that the intrauterine system (Mirena) may help dysmenorrhoea, but this only applies to normal copper coils.

Antepartum hemorrhage can be caused by placental abruption, which may result in vaginal bleeding, abdominal pain, and a firm or woody uterus. In some cases, the bleeding may be concealed, and the fetus may be difficult to feel or hear. It is important to note that young and healthy women may not show signs of shock until they have lost a significant amount of blood. Contractions during labor typically come in waves and do not cause a woody or tender uterus or low blood pressure. Placenta previa is another common cause of antepartum hemorrhage, but it is usually painless.

Placental Abruption: Causes, Symptoms, and Risk Factors

Placental abruption is a condition that occurs when the placenta separates from the uterine wall, leading to maternal bleeding into the space between them. Although the exact cause of this condition is unknown, certain factors have been associated with it, including proteinuric hypertension, cocaine use, multiparity, maternal trauma, and increasing maternal age. Placental abruption is not a common occurrence, affecting approximately 1 in 200 pregnancies.

The clinical features of placental abruption include shock that is disproportionate to the visible blood loss, constant pain, a tender and tense uterus, and a normal lie and presentation of the fetus. The fetal heart may be absent or distressed, and there may be coagulation problems. It is important to be aware of other conditions that may present with similar symptoms, such as pre-eclampsia, disseminated intravascular coagulation (DIC), and anuria.

In summary, placental abruption is a serious condition that can have significant consequences for both the mother and the fetus. Understanding the risk factors and symptoms of this condition is important for early detection and appropriate management.

Anticoagulant Therapy for Deep Vein Thrombosis in Pregnancy

Deep vein thrombosis (DVT) is a serious condition that can occur during pregnancy. Any woman with symptoms or signs suggestive of DVT should undergo objective testing and receive treatment with low-molecular-weight heparin (LMWH) immediately until the diagnosis is excluded. LMWH should be given in doses titrated against the woman’s weight and can be administered once daily or in two divided doses. It does not cross the placenta and has a lower risk of bleeding and heparin-induced osteoporosis compared to unfractionated heparin (UH). Fondaparinux, argatroban, or r-hirudin may be considered for pregnant women who cannot tolerate heparin.

Aspirin is not recommended for thromboprophylaxis in obstetric patients, except for pregnant women with a known history of antiphospholipid syndrome. Intravenous UH is the preferred initial treatment for massive pulmonary embolism with cardiovascular compromise during pregnancy and the puerperium. Warfarin should not be used for antenatal DVT treatment due to its adverse effects on the fetus. Postnatal therapy can be with LMWH or oral anticoagulants, but regular blood tests are needed to monitor warfarin.

Compression duplex ultrasonography should be performed when there is clinical suspicion of DVT. D-dimer testing should not be used in the investigation of acute DVT in pregnancy. Before anticoagulant therapy is started, blood tests should be taken for a full blood count, coagulation screen, urea and electrolytes, and liver function tests. Thrombophilia screening before therapy is not recommended.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Gynaecomastia may be linked to each of the remaining four drugs instead of galactorrhoea.

Understanding Prolactin and Galactorrhoea

Prolactin is a hormone produced by the anterior pituitary gland, and its release is regulated by various physiological factors. Dopamine is the primary inhibitor of prolactin release, and dopamine agonists like bromocriptine can be used to manage galactorrhoea. Galactorrhoea is a condition characterized by the production of breast milk in individuals who are not breastfeeding. It is important to distinguish the causes of galactorrhoea from those of gynaecomastia, which is the enlargement of male breast tissue.

Excess prolactin can lead to different symptoms in men and women. Men may experience impotence, loss of libido, and galactorrhoea, while women may have amenorrhoea and galactorrhoea. Several factors can cause raised prolactin levels, including prolactinoma, pregnancy, oestrogens, stress, exercise, sleep, acromegaly, polycystic ovarian syndrome, and primary hypothyroidism. Additionally, certain medications like metoclopramide, domperidone, phenothiazines, haloperidol, SSRIs, and opioids can also increase prolactin levels.

In summary, understanding prolactin and its effects on the body is crucial in diagnosing and managing conditions like galactorrhoea. Identifying the underlying causes of raised prolactin levels is essential in providing appropriate treatment and improving patient outcomes.

Understanding Lyme Disease

Lyme disease is a bacterial infection caused by Borrelia burgdorferi and is transmitted through tick bites. The early symptoms of Lyme disease include erythema migrans, a characteristic bulls-eye rash that appears at the site of the tick bite. This rash is painless, slowly increases in size, and can be more than 5 cm in diameter. Other early symptoms include headache, lethargy, fever, and joint pain.

If erythema migrans is present, Lyme disease can be diagnosed clinically, and antibiotics should be started immediately. The first-line test for Lyme disease is an enzyme-linked immunosorbent assay (ELISA) to detect antibodies to Borrelia burgdorferi. If the ELISA is negative but Lyme disease is still suspected, it should be repeated 4-6 weeks later. If Lyme disease is suspected in patients who have had symptoms for 12 weeks or more, an immunoblot test should be done.

Tick bites can cause significant anxiety, but routine antibiotic treatment is not recommended by NICE. If the tick is still present, it should be removed using fine-tipped tweezers, and the area should be washed. In cases of suspected or confirmed Lyme disease, doxycycline is the preferred treatment for early disease, while ceftriaxone is used for disseminated disease. A Jarisch-Herxheimer reaction may occur after initiating therapy, which can cause fever, rash, and tachycardia.

In summary, Lyme disease is a bacterial infection transmitted through tick bites. Early symptoms include erythema migrans, headache, lethargy, fever, and joint pain. Diagnosis is made through clinical presentation and ELISA testing, and treatment involves antibiotics. Tick bites do not require routine antibiotic treatment, and ticks should be removed using fine-tipped tweezers.

For women with risk factors for infertility, such as contralateral tube damage, salpingotomy should be considered as the preferred surgical management for ectopic pregnancy. In the case of this patient, who presented with acute-onset abdominal pain and vaginal bleeding 6-8 weeks after her last period, a positive pregnancy test, and ultrasound findings confirming ectopic pregnancy, surgical intervention is necessary. Given the size of the ectopic pregnancy and beta-hCG levels, either laparoscopic salpingectomy or salpingotomy is appropriate. However, since the patient has a history of PID and scarring of the contralateral tube, salpingotomy is the preferred option as it preserves the affected tube and her fertility. Expectant management, laparoscopic salpingectomy, and medical management with methotrexate are not appropriate for this patient’s case.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Women with premature ovarian insufficiency should be offered hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of 51 years to manage symptoms of low estrogen, prevent osteoporosis, and protect against possible cardiovascular complications. As this patient has a uterus, combined replacement therapy is necessary to avoid the risk of endometrial cancer from unopposed estrogen. Therefore, the most appropriate answer is combined hormone replacement therapy until the age of 51. It is important to note that hormone replacement therapy should be offered to all women with premature ovarian failure to protect bone mineral density and manage symptoms of low estrogen. The progestogen-only pill alone is not sufficient as estrogen is needed to treat symptoms and promote bone mineral density, while progesterone is added to oppose estrogen and reduce the risk of endometrial cancer.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Postcoital bleeding is most commonly caused by cervical ectropion.

Understanding Postcoital Bleeding

Postcoital bleeding refers to vaginal bleeding that occurs after sexual intercourse. In approximately 50% of cases, no identifiable pathology is found. However, cervical ectropion is the most common identifiable cause, accounting for around 33% of cases. This condition is more prevalent in women who are taking the combined oral contraceptive pill. Other potential causes of postcoital bleeding include cervicitis, which may be due to Chlamydia infection, cervical cancer, polyps, and trauma.

The copper intrauterine device is the recommended form of contraception for individuals with breast cancer. Hormonal forms of contraception are not recommended and are rated as a Category 4 risk, which is deemed unacceptable for the patient’s health.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

If a woman experiences pelvic pain during ovulation but does not have any vaginal bleeding, it may be Mittelschmerz. This type of pain is typically felt in the middle of the menstrual cycle. It is unlikely that a young patient with normal examination and intermittent abdominal pain during ovulation has ovarian malignancy. Additionally, there are no symptoms of hirsutism or changes to periods that suggest PCOS, nor are there any gastrointestinal symptoms that suggest IBS.

Understanding Mittelschmerz: Abdominal Pain Associated with Ovulation

Mittelschmerz, which translates to middle pain, is a type of abdominal pain that occurs during ovulation in approximately 20% of women. The exact cause of this mid-cycle pain is not fully understood, but there are several theories. One theory suggests that the pain is caused by the leakage of follicular fluid containing prostaglandins during ovulation. Another theory suggests that the growth of the follicle stretches the surface of the ovary, leading to pain.

The pain associated with Mittelschmerz typically presents suddenly in either iliac fossa and then spreads to the pelvic area. The pain is usually not severe and can last from minutes to hours. It is self-limiting and resolves within 24 hours of onset. The pain may switch sides from month to month, depending on the site of ovulation.

There are no specific tests to confirm Mittelschmerz, and it is diagnosed clinically after taking a full history and examination to exclude other conditions. Abdominal and pelvic examinations typically do not reveal any abnormal signs.

Mittelschmerz is not harmful and can be managed with simple analgesia. Understanding this condition can help women recognize and manage the pain associated with ovulation.

Implanon and Nexplanon are subdermal contraceptive implants that slowly release the progestogen hormone etonogestrel to prevent ovulation and thicken cervical mucus. Nexplanon is the newer version and has a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a past history of thromboembolism or migraine. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraceptive methods are required for the first 7 days if not inserted on days 1 to 5 of a woman’s menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs such as certain antiepileptic and rifampicin may reduce the efficacy of Nexplanon, and women should switch to a method unaffected by enzyme-inducing drugs or use additional contraception until 28 days after stopping the treatment.

There are also contraindications for using these implants, such as ischaemic heart disease/stroke, unexplained, suspicious vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Current breast cancer is a UKMEC 4 condition, which represents an unacceptable risk if the contraceptive method is used. Overall, these implants are a highly effective and long-acting form of contraception, but they require careful consideration of the potential risks and contraindications.

If females over 50 experience bloating and abdominal cramps, it is important to consider the possibility of ovarian cancer. The recommended course of action is to conduct a serum CA125 test. If the results show elevated levels, an abdominal and pelvic ultrasound should be scheduled. This information is based on NICE CG122 guidelines.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

There are several methods for screening and diagnosing Down’s syndrome in pregnancy. The nuchal translucency scan, which measures fluid in the fetal neck, is best done between 11 and 14 weeks and can detect an increased risk of genetic syndromes. The triple screen, which measures levels of certain hormones in the mother’s blood, is done in the second trimester and can detect up to 69% of cases in singleton pregnancies, but may have a higher false positive or false negative in twin pregnancies. Amniocentesis and chorionic villous sampling are invasive diagnostic tests that can detect chromosomal disorders with high accuracy, but carry a small risk of pregnancy loss. The routine anomaly scan should not be used for Down’s syndrome screening. Cell-free fetal DNA screening is a newer method that can detect about 99% of Down’s syndrome pregnancies, but is currently only offered by private clinics at a high cost. A positive screening result suggests an increased risk for Down’s syndrome, and definitive testing with chorionic villous sampling or amniocentesis is indicated.

Infertility may be linked to varicoceles.

Understanding Varicocele: Symptoms, Diagnosis, and Management

Varicocele is a medical condition characterized by the abnormal enlargement of the veins in the testicles. Although it is often asymptomatic, it can lead to infertility, making it an important condition to address. Varicoceles are more commonly found on the left side of the testicles, with over 80% of cases occurring on this side. The condition is often described as a bag of worms due to the appearance of the affected veins.

Diagnosis of varicocele is typically done through ultrasound with Doppler studies. This allows doctors to visualize the affected veins and determine the extent of the condition. While conservative management is often recommended, surgery may be necessary if the patient experiences pain or discomfort. However, there is ongoing debate regarding the effectiveness of surgery in treating infertility associated with varicocele.

Overall, understanding varicocele is important for men who may be experiencing infertility or other symptoms related to the condition. With proper diagnosis and management, it is possible to address the issue and improve overall reproductive health.

Screening for cervical cancer

Cervical Cancer Screening in the UK

Cervical cancer screening is a well-established program in the UK that aims to detect pre-malignant changes in the cervix. This program is estimated to prevent 1,000-4,000 deaths per year. However, it should be noted that around 15% of cervical adenocarcinomas are frequently undetected by screening.

The screening program has evolved significantly in recent years. Initially, smears were examined for signs of dyskaryosis, which may indicate cervical intraepithelial neoplasia. However, the introduction of HPV testing allowed for further risk stratification, and the NHS has now moved to an HPV first system. This means that a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

All women between the ages of 25-64 years are offered a smear test. Women aged 25-49 years are screened every three years, while those aged 50-64 years are screened every five years. However, cervical screening cannot be offered to women over 64. In Scotland, screening is offered from 25-64 every five years.

In special situations, cervical screening in pregnancy is usually delayed until three months post-partum, unless there are missed screenings or previous abnormal smears. Women who have never been sexually active have a very low risk of developing cervical cancer and may wish to opt-out of screening.

It is recommended to take a cervical smear around mid-cycle, although there is limited evidence to support this advice. Overall, the UK’s cervical cancer screening program is an essential tool in preventing cervical cancer and promoting women’s health.

Placenta praevia is a condition where the placenta is located in the lower part of the uterus, either partially or completely. If the placenta covers the internal cervical os, it is classified as major praevia, while it is considered minor or partial if it does not. Bleeding can occur spontaneously, due to trauma, or during labor as the cervix opens.

The Royal College of Obstetricians and Gynaecologists recommends considering placenta praevia in all cases of vaginal bleeding after 20 weeks of pregnancy. Symptoms that increase suspicion of this condition include painless bleeding, a high presenting part, and abnormal fetal lie. A definitive diagnosis usually requires an ultrasound to determine the position of the placenta.
(RCOG Green-top Guideline No. 27)

In this case, the absence of pain makes placental abruption unlikely, and the normal appearance of the cervix rules out cervical trauma, cervical neoplasm, and inevitable miscarriage as the cause.

Understanding Placenta Praevia

Placenta praevia is a condition where the placenta is located wholly or partially in the lower uterine segment. It is a relatively rare condition, with only 5% of women having a low-lying placenta when scanned at 16-20 weeks gestation. However, the incidence at delivery is only 0.5%, as most placentas tend to rise away from the cervix.

There are several factors associated with placenta praevia, including multiparity, multiple pregnancy, and embryos implanting on a lower segment scar from a previous caesarean section. Clinical features of placenta praevia include shock in proportion to visible loss, no pain, a non-tender uterus, abnormal lie and presentation, and a usually normal fetal heart. Coagulation problems are rare, and small bleeds may occur before larger ones.

Diagnosis of placenta praevia should not involve digital vaginal examination before an ultrasound, as this may provoke severe haemorrhage. The condition is often picked up on routine 20-week abdominal ultrasounds, but the Royal College of Obstetricians and Gynaecologists recommends the use of transvaginal ultrasound for improved accuracy and safety. Placenta praevia is classified into four grades, with grade IV being the most severe, where the placenta completely covers the internal os.

In summary, placenta praevia is a rare condition that can have serious consequences if not diagnosed and managed appropriately. It is important for healthcare professionals to be aware of the associated factors and clinical features, and to use appropriate diagnostic methods for accurate grading and management.

For the treatment of menorrhagia, the first-line option would be the intrauterine system. Specifically, the Mirena, which contains levonorgestrel, is highly effective in treating menorrhagia and also serves as a long-acting reversible contraceptive. While the combined oral contraceptive pill, tranexamic acid, and mefenamic acid may provide relief from symptoms, they are not the preferred initial treatment. On the other hand, the intrauterine device would not be suitable for addressing this patient’s menorrhagia.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

The gestational diabetes guidelines of NICE have been updated, stating that insulin treatment must commence if the fasting glucose level is equal to or greater than 7 mmol/l. Additionally, it is recommended to consider administering aspirin due to the heightened risk of pre-eclampsia.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

Management of Fibrocystic Breast Disease: Referral to Breast Surgery Team

Fibrocystic breast disease, also known as fibro-adenosis or fibrosclerosis, is a common benign condition that often presents with breast lumps or nodularity. According to National Institute for Health and Care Excellence (NICE) guidelines, patients under 30 years of age with a new breast lump without other suspicious features should be routinely referred to the Breast Clinic.

For patients presenting with a persistent lump, watch and wait may not be appropriate, and referral for assessment is indicated. Urgent 2-week wait referral is recommended for patients over 30 years of age with a new unexplained breast or axillary lump, or skin or nipple changes suggestive of breast cancer.

Mammography is not indicated for patients under 35 years of age with a suspected fibro-adenoma. Instead, triple assessment with ultrasonography is recommended. Antibiotics are not indicated unless there is evidence of infection or abscess.

Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

Managing Menopause: Lifestyle Modifications, Hormone Replacement Therapy, and Non-Hormone Replacement Therapy

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 consecutive months. Menopausal symptoms are common and can last for up to 7 years, with varying degrees of severity and duration. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage menopausal symptoms such as hot flushes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended. For women who cannot or do not want to take HRT, non-hormonal treatments such as fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturizers for vaginal dryness, and cognitive behavior therapy or antidepressants for psychological symptoms can be prescribed.

HRT is a treatment option for women with moderate to severe menopausal symptoms. However, it is contraindicated in women with current or past breast cancer, any estrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia. HRT brings certain risks, including venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer. Women should be advised of these risks and the fact that symptoms typically last for 2-5 years.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence of symptoms in the short term. However, in the long term, there is no difference in symptom control. Women who experience ineffective treatment, ongoing side effects, or unexplained bleeding should be referred to secondary care. Overall, managing menopause requires a personalized approach that takes into account a woman’s medical history, preferences, and individual symptoms.

It was once believed that taking antibiotics while on any form of contraceptive pill could reduce the pill’s effectiveness. However, it is now known that broad-spectrum antibiotics do not interact with the progesterone-only pill, and therefore no extra precautions are necessary. The only exception is enzyme-inducing antibiotics like rifampicin, which may affect the pill’s efficacy. Additionally, if an antibiotic causes vomiting or diarrhea, it may also affect the pill’s effectiveness, but this is true for any form of vomiting or diarrhea. Therefore, the correct advice is to reassure patients that no additional precautions are needed. Advising the use of barrier contraceptives or ceasing the pill is incorrect, as there is no evidence to support these actions.

Counselling for Women Considering the Progestogen-Only Pill

Women who are considering taking the progestogen-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. When starting the POP, immediate protection is provided if it is commenced up to and including day 5 of the cycle. If it is started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a combined oral contraceptive (COC), immediate protection is provided if the POP is continued directly from the end of a pill packet.

It is important to take the POP at the same time every day, without a pill-free break, unlike the COC. If a pill is missed by less than 3 hours, it should be taken as normal. If it is missed by more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours. Diarrhoea and vomiting do not affect the POP, but assuming pills have been missed and following the above guidelines is recommended. Antibiotics have no effect on the POP, unless they alter the P450 enzyme system, such as rifampicin. Liver enzyme inducers may reduce the effectiveness of the POP.

In addition to these specific guidelines, women should also have a discussion on sexually transmitted infections (STIs) when considering the POP. It is important for women to receive comprehensive counselling on the POP to ensure they are aware of its potential effects and how to use it effectively.

The initial treatment for primary dysmenorrhoea, which this girl is experiencing, is NSAIDs like mefenamic acid. There is no need for gynaecological investigation at this point. If mefenamic acid does not work, she could consider taking the combined oral contraceptive pill, but since she is not sexually active, it may not be necessary. Tranexamic acid is helpful for menorrhagia, but it will not alleviate pain. A transvaginal ultrasound scan is not necessary for primary dysmenorrhoea.

Dysmenorrhoea is a condition where women experience excessive pain during their menstrual period. There are two types of dysmenorrhoea: primary and secondary. Primary dysmenorrhoea affects up to 50% of menstruating women and is not caused by any underlying pelvic pathology. It usually appears within 1-2 years of the menarche and is thought to be partially caused by excessive endometrial prostaglandin production. Symptoms include suprapubic cramping pains that may radiate to the back or down the thigh, and pain typically starts just before or within a few hours of the period starting. NSAIDs such as mefenamic acid and ibuprofen are effective in up to 80% of women, and combined oral contraceptive pills are used second line for management.

Secondary dysmenorrhoea, on the other hand, typically develops many years after the menarche and is caused by an underlying pathology. The pain usually starts 3-4 days before the onset of the period. Causes of secondary dysmenorrhoea include endometriosis, adenomyosis, pelvic inflammatory disease, intrauterine devices, and fibroids. Clinical Knowledge Summaries recommend referring all patients with secondary dysmenorrhoea to gynaecology for investigation. It is important to note that the intrauterine system (Mirena) may help dysmenorrhoea, but this only applies to normal copper coils.

Levonorgestrel (Levonelle) can be followed immediately by hormonal contraception for emergency contraception.

Patients can resume their regular pill regimen right after taking levonorgestrel for emergency contraception. Levonorgestrel is an approved method of emergency contraception that can be used within 72 hours of unprotected sexual intercourse. It is the preferred oral emergency contraceptive for patients with asthma, as ulipristal is not recommended for those with severe asthma. Unlike ulipristal, which requires a waiting period of 5 days, patients can start hormonal contraception immediately after taking levonorgestrel. However, patients should use condoms for 7 days after restarting their combined oral contraceptive pill (COCP). It is important to note that the other options provided are incorrect. The progesterone-only pill requires condom use for 48 hours, unless initiated within the first 5 days of the menstrual cycle. Ulipristal acetate requires a waiting period of 5 days before restarting hormonal contraception. The COCP requires condom use for 7 days after restarting.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Medical treatment can be attempted for uterine fibroids that are smaller than 3 cm and do not distort the uterine cavity. This may include options such as an intrauterine system, tranexamic acid, or COCP. The NICE Clinical Knowledge Summaries suggest starting with an intrauterine system, which can also serve as a form of contraception.

Understanding Uterine Fibroids

Uterine fibroids are non-cancerous growths that develop in the uterus. They are more common in black women and are thought to occur in around 20% of white women in their later reproductive years. Fibroids are usually asymptomatic, but they can cause menorrhagia, which can lead to iron-deficiency anaemia. Other symptoms include lower abdominal pain, bloating, and urinary symptoms. Fibroids may also cause subfertility.

Diagnosis is usually made through transvaginal ultrasound. Asymptomatic fibroids do not require treatment, but periodic monitoring is recommended. Menorrhagia secondary to fibroids can be managed with various treatments, including the levonorgestrel intrauterine system, NSAIDs, tranexamic acid, and hormonal therapies.

Medical treatment to shrink or remove fibroids may include GnRH agonists or ulipristal acetate, although the latter is not currently recommended due to concerns about liver toxicity. Surgical options include myomectomy, hysteroscopic endometrial ablation, hysterectomy, and uterine artery embolization.

Fibroids generally regress after menopause, but complications such as subfertility and iron-deficiency anaemia can occur. Red degeneration, which is haemorrhage into the tumour, is a common complication during pregnancy.

Understanding Trichomonas vaginalis and its Comparison to Bacterial Vaginosis

Trichomonas vaginalis is a type of protozoan parasite that is highly motile and flagellated. It is known to cause trichomoniasis, which is a sexually transmitted infection. The infection is characterized by symptoms such as offensive, yellow/green, frothy vaginal discharge, vulvovaginitis, and strawberry cervix. The pH level is usually above 4.5, and in men, it may cause urethritis.

To diagnose trichomoniasis, a wet mount microscopy is conducted to observe the motile trophozoites. The treatment for trichomoniasis involves oral metronidazole for 5-7 days, although a one-off dose of 2g metronidazole may also be used.

When compared to bacterial vaginosis, trichomoniasis has distinct differences. Bacterial vaginosis is caused by an overgrowth of bacteria in the vagina, while trichomoniasis is caused by a protozoan parasite. The symptoms of bacterial vaginosis include a thin, grayish-white vaginal discharge with a fishy odor, and a pH level above 4.5. Unlike trichomoniasis, bacterial vaginosis is not considered a sexually transmitted infection.

In conclusion, understanding the differences between trichomoniasis and bacterial vaginosis is crucial in diagnosing and treating these conditions effectively. Proper diagnosis and treatment can help prevent complications and improve overall health and well-being.

When it comes to methotrexate, it is important to discontinue the drug at least six months before attempting to conceive, regardless of gender. This is because methotrexate can potentially harm sperm in males and cause early abortion in females. By allowing for a full wash-out period, the risk of DNA changes in both gametes can be minimized. While some studies suggest that paternal exposure to methotrexate within 90 days before pregnancy may not lead to congenital malformations, stillbirths, or preterm births, current guidelines recommend avoiding the drug for six months to ensure proper folic acid repletion. Therefore, options suggesting stopping methotrexate for only one or three months before conception are incorrect.

Managing Rheumatoid Arthritis During Pregnancy

Rheumatoid arthritis (RA) is a condition that commonly affects women of reproductive age, making issues surrounding conception and pregnancy a concern. While there are no official guidelines for managing RA during pregnancy, expert reviews suggest that patients with early or poorly controlled RA should wait until their disease is more stable before attempting to conceive.

During pregnancy, RA symptoms tend to improve for most patients, but only a small minority experience complete resolution. After delivery, patients often experience a flare-up of symptoms. It’s important to note that certain medications used to treat RA are not safe during pregnancy, such as methotrexate and leflunomide. However, sulfasalazine and hydroxychloroquine are considered safe.

Interestingly, studies have shown that the use of TNF-α blockers during pregnancy does not significantly increase adverse outcomes. However, many patients in these studies stopped taking the medication once they found out they were pregnant. Low-dose corticosteroids may also be used to control symptoms during pregnancy.

NSAIDs can be used until 32 weeks, but should be withdrawn after that due to the risk of early closure of the ductus arteriosus. Patients with RA should also be referred to an obstetric anaesthetist due to the risk of atlanto-axial subluxation. Overall, managing RA during pregnancy requires careful consideration and consultation with healthcare professionals.

The most suitable emergency contraception option in this case is the copper intrauterine device, which can be inserted up to 5 days after the estimated ovulation date or the first instance of unprotected sexual intercourse in a cycle, whichever is later. As ovulation is likely to have already occurred (estimated as day 14, now on day 17), the copper IUD is the most effective option. It is considered the most reliable form of emergency contraception and should be offered to all patients unless there are contraindications. If the patient declines or the IUD is contraindicated, one of the hormonal pill options may be offered, although they may be less effective in this case. The Mirena intrauterine system is not suitable for emergency contraception as it has a delayed action. It is important to offer emergency contraception to all women who request it, even if it falls outside the recommended window of use, and to inform them that it may not be completely effective in preventing pregnancy.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

The appropriate medical treatments for postpartum haemorrhage caused by uterine atony are oxytocin, ergometrine, carboprost, and misoprostol. In this scenario, the patient has experienced a blood loss of over 500 ml after delivery, indicating PPH as the likely cause, with uterine atony being the most probable reason. The first steps in managing PPH involve an ABCDE approach, including IV access, warm crystalloid administration, uterine fundus palpation, and catheterisation to prevent bladder distention. If these measures fail, medical therapy is initiated, starting with IV oxytocin. IM carboprost is not the correct choice as it requires senior approval and can worsen bronchoconstriction in patients with asthma. IV carboprost is also not recommended as it can cause bronchospasm, hypertension, and fever, and requires senior approval. IV tocolytics are not appropriate as they suppress uterine contractions, which would exacerbate the problem in this case. Therefore, agents that stimulate uterine contraction are given to manage PPH caused by uterine atony.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage (PPH) is a condition where a woman experiences blood loss of more than 500 ml after giving birth vaginally. It can be classified as primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia.

In managing PPH, it is important to involve senior staff immediately and follow the ABC approach. This includes two peripheral cannulae, lying the woman flat, blood tests, and commencing a warmed crystalloid infusion. Mechanical interventions such as rubbing up the fundus and catheterisation are also done. Medical interventions include IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options such as intrauterine balloon tamponade, B-Lynch suture, ligation of uterine arteries, and hysterectomy may be considered if medical options fail to control the bleeding.

Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to understand the causes and risk factors of PPH to prevent and manage this life-threatening emergency effectively.

Taking metronidazole and alcohol together can result in a disulfiram-like reaction, so patients should be cautioned against consuming alcohol while on the medication. Metronidazole is not associated with cholestasis, hepatotoxicity, or QT prolongation. As an enzyme inhibitor, metronidazole enhances the efficacy of the COCP. While Stevens-Johnson syndrome is a rare side effect of metronidazole, a photosensitive rash is not typically observed.

Metronidazole is an antibiotic that functions by producing reactive cytotoxic metabolites within bacteria. This medication can cause adverse effects such as a disulfiram-like reaction when combined with alcohol and an increased anticoagulant effect when taken with warfarin.

The prognosis for endometrial cancer is generally favorable.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. Progestogen therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

When simple analgesia fails to alleviate endometriosis-related pain, the next step in treatment is to try either progestogens or the combined oral contraceptive pill. These hormonal treatments are generally effective in managing the symptoms of endometriosis. While clomifene may be used to induce ovulation in certain conditions, it is not the recommended next step in pain management for endometriosis. Elagolix, a new gonadotropin-releasing hormone antagonist, is licensed in the USA for endometriosis-related pain but is not widely used in the UK. Laparoscopic excision is a more invasive option and is typically reserved for later stages of treatment. Therefore, hormonal options are the next most appropriate step after simple analgesia for managing endometriosis-related pain.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

According to NICE guidelines, clinicians should diagnose pelvic inflammatory disease based on clinical symptoms and start antibiotic treatment promptly. While investigations such as endocervical and high vaginal swabs for microscopy and culture should be performed, they should not delay treatment. Negative swab results do not exclude the possibility of the disease. Blood cultures are not necessary unless the patient shows signs of systemic illness. Transvaginal ultrasound is not the first choice but may be necessary if an abscess is suspected.
(NICE CKS – Pelvic Inflammatory Disease)

Understanding Pelvic Inflammatory Disease

Pelvic inflammatory disease (PID) is a condition that occurs when the female pelvic organs, including the uterus, fallopian tubes, ovaries, and surrounding peritoneum, become infected and inflamed. The most common cause of PID is an ascending infection from the endocervix, often caused by Chlamydia trachomatis. Other causative organisms include Neisseria gonorrhoeae, Mycoplasma genitalium, and Mycoplasma hominis. Symptoms of PID include lower abdominal pain, fever, dyspareunia, dysuria, menstrual irregularities, vaginal or cervical discharge, and cervical excitation.

To diagnose PID, a pregnancy test should be done to rule out an ectopic pregnancy, and a high vaginal swab should be taken to screen for Chlamydia and Gonorrhoea. However, these tests are often negative, so consensus guidelines recommend having a low threshold for treatment due to the potential complications of untreated PID. Management typically involves a combination of antibiotics, such as oral ofloxacin and oral metronidazole or intramuscular ceftriaxone, oral doxycycline, and oral metronidazole.

Complications of PID include perihepatitis (Fitz-Hugh Curtis Syndrome), which occurs in around 10% of cases and is characterized by right upper quadrant pain that may be confused with cholecystitis. PID can also lead to infertility, with the risk as high as 10-20% after a single episode, chronic pelvic pain, and ectopic pregnancy. In mild cases of PID, intrauterine contraceptive devices may be left in, but recent guidelines suggest that removal of the IUD should be considered for better short-term clinical outcomes. Understanding PID and its potential complications is crucial for early diagnosis and effective management.

Understanding Herpes Simplex Virus

Herpes simplex virus (HSV) is a common viral infection that affects humans. There are two strains of the virus, HSV-1 and HSV-2, which were previously thought to cause oral and genital herpes, respectively. However, there is now considerable overlap between the two strains. The primary infection may present with severe gingivostomatitis, while cold sores and painful genital ulceration are common features.

Management of HSV includes oral aciclovir for gingivostomatitis and genital herpes, and topical aciclovir for cold sores, although the evidence base for the latter is modest. Patients with frequent exacerbations may benefit from longer-term aciclovir. In pregnant women, a primary attack of herpes during pregnancy at greater than 28 weeks gestation may require elective caesarean section at term. Women with recurrent herpes who are pregnant should be treated with suppressive therapy and advised that the risk of transmission to their baby is low.

The cytopathic effect of HSV can be seen in Pap smears, which show multinucleated giant cells representing infection by the virus. The 3 M’s – multinucleation, margination of the chromatin, and molding of the nuclei – are characteristic features of HSV infection. Understanding the features and management of HSV is important for effective treatment and prevention of transmission.

The Mirena intrauterine system is approved for use as the progesterone component of hormone replacement therapy for a duration of 4 years. In a woman with a uterus, hormone replacement therapy aims to replace oestrogen to alleviate menopausal symptoms, but an additional source of progesterone is required to counteract the effects of unopposed oestrogen on the uterus, which increases the risk of endometrial hyperplasia and malignancy. As this patient already has the Mirena coil in place, which releases progesterone locally to act on the uterus, the only necessary treatment is oestrogen. Estradiol is the only option that provides only oestrogen therapy and can be administered topically or transdermally. Combined HRT, which includes both oestrogen and progesterone, would be inappropriate as the patient is already receiving progesterone from the Mirena coil. Levonorgestrel and medroxyprogesterone are both progesterones and would not provide oestrogen supplementation to the patient, which is necessary to alleviate her menopausal symptoms.

Managing Menopause: Lifestyle Modifications, Hormone Replacement Therapy, and Non-Hormone Replacement Therapy

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 consecutive months. Menopausal symptoms are common and can last for up to 7 years, with varying degrees of severity and duration. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage menopausal symptoms such as hot flushes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended. For women who cannot or do not want to take HRT, non-hormonal treatments such as fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturizers for vaginal dryness, and cognitive behavior therapy or antidepressants for psychological symptoms can be prescribed.

HRT is a treatment option for women with moderate to severe menopausal symptoms. However, it is contraindicated in women with current or past breast cancer, any estrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia. HRT brings certain risks, including venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer. Women should be advised of these risks and the fact that symptoms typically last for 2-5 years.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence of symptoms in the short term. However, in the long term, there is no difference in symptom control. Women who experience ineffective treatment, ongoing side effects, or unexplained bleeding should be referred to secondary care. Overall, managing menopause requires a personalized approach that takes into account a woman’s medical history, preferences, and individual symptoms.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucus thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

The symphysis-fundal height in centimeters after 20 weeks of gestation is equal to the number of weeks of gestation.

The symphysis-fundal height (SFH) is a measurement taken from the pubic bone to the top of the uterus in centimetres. It is used to determine the gestational age of a fetus and should match within 2 cm after 20 weeks. For example, if a woman is 24 weeks pregnant, a normal SFH would be between 22 and 26 cm. Proper measurement of SFH is important for monitoring fetal growth and development during pregnancy.

In cases where a pregnant woman is exposed to chickenpox and her immunity status is uncertain, it is recommended to conduct a blood test to check for varicella antibodies. If she is found to be not immune and is over 20 weeks pregnant, either VZIG or aciclovir can be given. However, VZIG is the only option for those under 20 weeks pregnant and not immune. It is important to note that VZIG is effective up to 10 days post-exposure, so there is no need to administer it immediately after the blood test. Prescribing medication without confirming the patient’s immunity status is not recommended. Similarly, reassuring the patient and sending her away without following proper prophylaxis protocol is not appropriate. It is also important to note that the varicella-zoster vaccine is not currently part of the UK’s vaccination schedule and does not play a role in the management of pregnant women.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Fertility Management in Men: Appropriate Investigations and Management Options

When it comes to fertility management in men, it is important to follow the guidelines set by the National Institute for Health and Care Excellence (NICE). According to NICE, couples who have been trying to conceive for a year with regular intercourse should be referred to fertility services. However, earlier investigation may be necessary if there is an underlying medical reason for conception difficulties. This means that watching and waiting for 12 months is the appropriate management option in most cases.

One of the investigations that may be necessary is a semen analysis, which is indicated after a year of trying to conceive. Testicular biopsy, on the other hand, is only necessary if there is a potential testicular carcinoma or for sperm retrieval for in-vitro fertilisation (IVF) procedures.

While screening for anti-sperm antibodies may be necessary in secondary care, it is not usually arranged in primary care. Similarly, screening for gonorrhoea is not part of the investigations for reduced fertility as it does not have a significant effect on a patient’s ability to conceive and is not usually asymptomatic. However, excluding asymptomatic chlamydia infection is an important part of the investigation for patients who are struggling with reduced fertility.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

To confirm ovulation in patients struggling to conceive, a serum progesterone level should be taken 7 days prior to the expected next period. This timing coincides with ovulation and is the most accurate way to confirm it. Taking the test 14 days before the next expected period or on the first day of the next period would not be timed correctly. It is also important to note that the timing of intercourse does not affect the confirmation of ovulation through serum progesterone testing.

Infertility is a common issue that affects approximately 1 in 7 couples. It is important to note that around 84% of couples who have regular sexual intercourse will conceive within the first year, and 92% within the first two years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

When investigating infertility, there are some basic tests that can be done. These include a semen analysis and a serum progesterone test. The serum progesterone test is done 7 days prior to the expected next period, typically on day 21 for a 28-day cycle. The interpretation of the serum progesterone level is as follows: if it is less than 16 nmol/l, it should be repeated and if it remains consistently low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

It is important to counsel patients on lifestyle factors that can impact fertility. This includes taking folic acid, maintaining a healthy BMI between 20-25, and advising regular sexual intercourse every 2 to 3 days. Additionally, patients should be advised to quit smoking and limit alcohol consumption to increase their chances of conceiving.

If a foetal heartbeat is detected on ultrasound in the case of an ectopic pregnancy, surgical management is necessary, and the appropriate procedure is a salpingectomy. This is the recommended course of action for a patient with no significant medical history and both fallopian tubes. Expectant management is not suitable in this scenario, as the foetal heartbeat is visible on ultrasound. Medical management with methotrexate is also not an option due to the foetal heartbeat, and mifepristone is not used for ectopic pregnancies.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingotomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women with no other risk factors for infertility, while salpingotomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingotomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Management of Syphilis

Syphilis can be effectively managed with intramuscular benzathine penicillin as the first-line treatment. In cases where penicillin cannot be used, doxycycline may be used as an alternative. After treatment, nontreponemal titres such as rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) should be monitored to assess the response. A fourfold decline in titres is often considered an adequate response to treatment.

It is important to note that the Jarisch-Herxheimer reaction may occur following treatment. This reaction is characterized by fever, rash, and tachycardia after the first dose of antibiotic. Unlike anaphylaxis, there is no wheezing or hypotension. The reaction is thought to be due to the release of endotoxins following bacterial death and typically occurs within a few hours of treatment. However, no treatment is needed other than antipyretics if required.

In summary, the management of syphilis involves the use of intramuscular benzathine penicillin or doxycycline as an alternative. Nontreponemal titres should be monitored after treatment, and the Jarisch-Herxheimer reaction may occur but does not require treatment unless symptomatic.

Currently, there is no dependable screening test for detecting ovarian cancer in its early stages. However, women, especially those over 50 years old, who experience persistent symptoms such as abdominal bloating, early satiety, loss of appetite, pelvic or abdominal pain, and increased urinary urgency or frequency should be suspected of having ovarian cancer and should undergo further tests.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

Miscarriage is a common complication that can occur in up to 25% of all pregnancies. There are different types of miscarriage, each with its own set of symptoms and characteristics. Threatened miscarriage is painless vaginal bleeding that occurs before 24 weeks, typically at 6-9 weeks. The bleeding is usually less than menstruation, and the cervical os is closed. Missed or delayed miscarriage is when a gestational sac containing a dead fetus is present before 20 weeks, without the symptoms of expulsion. The mother may experience light vaginal bleeding or discharge, and the symptoms of pregnancy may disappear. Pain is not usually a feature, and the cervical os is closed. Inevitable miscarriage is characterized by heavy bleeding with clots and pain, and the cervical os is open. Incomplete miscarriage occurs when not all products of conception have been expelled, and there is pain and vaginal bleeding. The cervical os is open in this type of miscarriage.

Urinary tract infections in pregnancy should be treated to prevent pyelonephritis. Trimethoprim should be avoided in the first trimester due to teratogenicity risk. Erythromycin is not typically used for UTIs and nitrofurantoin should be avoided close to full term. Sulfonamides and quinolones should also be avoided in pregnancy.

Urinary tract infections (UTIs) are common in adults and can affect different parts of the urinary tract. The management of UTIs depends on various factors such as the patient’s age, gender, and pregnancy status. For non-pregnant women, local antibiotic guidelines should be followed if available. Trimethoprim or nitrofurantoin for three days are recommended by NICE Clinical Knowledge Summaries. However, if the patient is aged over 65 years or has visible or non-visible haematuria, a urine culture should be sent. Pregnant women with UTIs should be treated with nitrofurantoin, amoxicillin, or cefalexin for seven days. Trimethoprim should be avoided during pregnancy as it is teratogenic in the first trimester. Asymptomatic bacteriuria in pregnant women should also be treated to prevent progression to acute pyelonephritis. Men with UTIs should be offered a seven-day course of trimethoprim or nitrofurantoin unless prostatitis is suspected. A urine culture should be sent before antibiotics are started. Catheterised patients should not be treated for asymptomatic bacteria, but if symptomatic, a seven-day course of antibiotics should be given. Acute pyelonephritis requires hospital admission and treatment with a broad-spectrum cephalosporin or quinolone for 10-14 days. Referral to urology is not routinely required for men who have had one uncomplicated lower UTI.

Progestogen Only Pill: What to Do When You Miss a Pill

The progestogen only pill (POP) has simpler rules for missed pills compared to the combined oral contraceptive pill. It is important to note that the rules for the two types of pills should not be confused. The traditional POPs (Micronor, Noriday, Nogeston, Femulen) and Cerazette (desogestrel) have the following guidelines for missed pills:

– If the pill is less than 3 hours late, no action is required, and you can continue taking the pill as normal.
– If the pill is more than 3 hours late (i.e., more than 27 hours since the last pill was taken), action is needed.
– If the pill is less than 12 hours late, no action is required, and you can continue taking the pill as normal.
– If the pill is more than 12 hours late (i.e., more than 36 hours since the last pill was taken), action is needed.

Oral labetalol is the recommended initial treatment for this woman with moderate gestational hypertension, as per the current guidelines.

Hypertension during pregnancy is a common occurrence that requires careful management. In normal pregnancies, blood pressure tends to decrease in the first trimester and then gradually increase to pre-pregnancy levels by term. However, in cases of hypertension during pregnancy, the systolic blood pressure is usually above 140 mmHg or the diastolic blood pressure is above 90 mmHg. Additionally, an increase of more than 30 mmHg systolic or 15 mmHg diastolic from the initial readings may also indicate hypertension.

There are three categories of hypertension during pregnancy: pre-existing hypertension, pregnancy-induced hypertension (PIH), and pre-eclampsia. Pre-existing hypertension refers to a history of hypertension before pregnancy or elevated blood pressure before 20 weeks gestation. PIH occurs in the second half of pregnancy and resolves after birth. Pre-eclampsia is characterized by hypertension and proteinuria, and may also involve edema.

The management of hypertension during pregnancy involves the use of antihypertensive medications such as labetalol, nifedipine, and hydralazine. In cases of pre-existing hypertension, ACE inhibitors and angiotensin II receptor blockers should be stopped immediately and alternative medications should be prescribed. Women who are at high risk of developing pre-eclampsia should take aspirin from 12 weeks until the birth of the baby. It is important to carefully monitor blood pressure and proteinuria levels during pregnancy to ensure the health of both the mother and the baby.

Understanding Endometrial Cancer: Causes, Stages, and Treatment Options

Endometrial cancer is a type of cancer that affects the lining of the uterus. It is the most common female genital cancer in the developing world, and an estimated 3% of women in developed countries will be diagnosed with this malignancy at some point in their lifetime. Here are some key points to understand about endometrial cancer:

Causes:
– It is more common among women using progestogen-containing oral contraceptives.
– Non-hormonal uterine devices have also been found to be strongly protective.
– There are two pathogenic types of endometrial cancer, one of which is associated with obesity, hyperlipidaemia, signs of hyperoestrogenism, and other disease states.

Stages:
– The FIGO staging system is used to determine the stage of endometrial cancer.
– Staging is the most important prognostic factor.
– The earlier endometrial cancer is diagnosed, the higher the rate of survival at 5 years.

Treatment:
– Standard management of endometrial cancer at diagnosis involves surgery, followed by chemotherapy with or without radiation therapy.
– It is most effectively treated by a combination of radiotherapy and hormone-based chemotherapy.
– The prognosis varies depending on the stage and type of endometrial cancer.

Overall, understanding the causes, stages, and treatment options for endometrial cancer is important for early detection and effective management of this malignancy.

Pregnant women with symptomatic bacterial vaginosis (BV) should be offered treatment using oral metronidazole. If BV is incidentally detected in a pregnant woman without symptoms, it is advisable to discuss with her obstetrician whether treatment is necessary. High-dose regimens are not recommended during pregnancy. In case the woman prefers a topical treatment or is unable to tolerate oral metronidazole, intravaginal metronidazole gel or clindamycin cream can be used as alternative choices. However, oral clindamycin is not widely recommended in primary care due to the increased risk of pseudomembranous colitis. This information is sourced from NICE CKS – Bacterial Vaginosis.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

To ensure the effectiveness of the contraceptive patch, it should be applied to clean, dry skin on a weekly basis for three weeks, followed by a patch-free week to stimulate a withdrawal bleed. However, if the patch change is delayed for more than 48 hours, it is important to change it immediately and use a barrier method of contraception for the next 7 days. In case of unprotected intercourse, emergency contraceptives should be considered.

The Evra patch is the only contraceptive patch that is approved for use in the UK. The patch cycle lasts for four weeks, during which the patch is worn every day for the first three weeks and changed weekly. During the fourth week, the patch is not worn, and a withdrawal bleed occurs.

If a woman delays changing the patch at the end of week one or two, she should change it immediately. If the delay is less than 48 hours, no further precautions are necessary. However, if the delay is more than 48 hours, she should change the patch immediately and use a barrier method of contraception for the next seven days. If she has had unprotected sex during this extended patch-free interval or in the last five days, emergency contraception should be considered.

If the patch removal is delayed at the end of week three, the woman should remove the patch as soon as possible and apply a new patch on the usual cycle start day for the next cycle, even if withdrawal bleeding is occurring. No additional contraception is needed.

If patch application is delayed at the end of a patch-free week, additional barrier contraception should be used for seven days following any delay at the start of a new patch cycle. For more information, please refer to the NICE Clinical Knowledge Summary on combined hormonal methods of contraception.

Premature menopause is characterized by irregular menstrual cycles occurring before the age of 45, along with elevated FSH/LH levels and low oestradiol levels in blood tests. The pituitary gland releases more hormones in an attempt to stimulate the failing ovary to produce oestrogen, resulting in a negative feedback loop. Therefore, options 1, 3, 4, and 5 are incorrect. Option 5 depicts primary pituitary failure.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Weight loss before pregnancy
Lack of proper hydration
Disruption in electrolyte balance

Hyperemesis gravidarum is an extreme form of nausea and vomiting of pregnancy that occurs in around 1% of pregnancies and is most common between 8 and 12 weeks. It is associated with raised beta hCG levels and can be caused by multiple pregnancies, trophoblastic disease, hyperthyroidism, nulliparity, and obesity. Referral criteria for nausea and vomiting in pregnancy include continued symptoms with ketonuria and/or weight loss, a confirmed or suspected comorbidity, and inability to keep down liquids or oral antiemetics. The diagnosis of hyperemesis gravidarum requires the presence of 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance. Management includes first-line use of antihistamines and oral cyclizine or promethazine, with second-line options of ondansetron and metoclopramide. Admission may be needed for IV hydration. Complications can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth issues.